Blincyto
Blincyto ingredients
| Active ingredient | Strength |
|---|---|
| Blinatumomab | see label |
What Blincyto is used for
The FDA lists the approved uses on the official label (below). In the EU, blinatumomab is approved as Blincyto for:
Blincyto is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B‑cell precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome-positive B-cell precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options. Blincyto is indicated as monotherapy for the treatment of adults with Philadelphia chromosome-negative CD19 positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 month or older with Philadelphia chromosome-negative CD19 positive B‑cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haemato…
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Blincyto
- Generic name
- Blinatumomab
- Made by
- Amgen, Inc
- Forms
- Kit
- FDA approval
- Biologic licence (BLA) BLA125557
- On the US market since
- 2014
Official information
- Blincyto prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Blinatumomab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Blincyto?
Blincyto (Blinatumomab) is a cancer medicine made by Amgen, Inc, approved by the US FDA.
What are the ingredients of Blincyto?
Blincyto contains Blinatumomab.
Is Blincyto approved in Europe?
The same active substance is approved in the EU as Blincyto.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA